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Over the 15-year period 1989–2003, the incidence of oesophagus–cardia adenocarcinoma in the Netherlands rose annually by 2.6%
for males and 1.2% for females. This was the net outcome of annual increases in the incidence of adenocarcinoma of the oesophagus
(ACO) of 7.2% for males and 3.5% for females and annual declines in the incidence of adenocarcinoma of the gastric cardia (AGC) of
more than 1% for both genders. Nonlinear cohort patterns were found in females with ACO and for both genders in AGC; a
nonlinear period pattern was observed only in males with AGC. These differing epidemiological patterns for ACO and AGC do not
support a common aetiology. Proposed underlying factors for the rise in ACO incidence appear to have little effect on AGC
incidence. This and the secular decline in smoking among males may have led to the decline in AGC incidence.
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Over the past 30 years, the incidence of adenocarcinoma of the
oesophagus (ACO) has gradually exceeded that of squamous cell
carcinoma (Heitmiller and Sharma, 1996).
The recognition that in the oesophagus, adenocarcinomas can
(Morson and Belcher, 1952; Naef et al, 1975) and mainly do
(Haggitt et al, 1978) develop in a columnar-lined (Barrett’s)
oesophagus has underlined the necessity of distinguishing between
these adenocarcinomas (ACO) and the adenocarcinomas of the
gastric cardia (AGC), which do not originate in the oesophagus.
Where this distinction is not made, we employ the term
oesophagus–cardia adenocarcinoma. A steady rise in the in-
cidence rates of the oesophagus–cardia adenocarcinoma has
been reported from the United States and Europe (Bollschweiler
et al, 2001; El-Serag, 2002). However, whether this rise involved
both ACO and AGC to the same extent has remained unclear,
as most registries did not distinguish them. This is not surprising
because, even for pathologists examining resected specimens,
the distinction is often problematic (Siewert and Stein, 1998;
Driessen et al, 2003). In Denmark, in the period 1989–1995, an
AGC to ACO incidence ratio of 1.8–1 in males was reported
(Eurocim, 2001); a panel of experts reviewing the original
clinical data reversed this ratio to 1–2.4 (van Blankenstein et al,
2005). The Netherlands is among those countries that have
the highest incidence rates of both ACO and AGC (Corley and
Buffler, 2001).
By analysing the differential time trends in ACO and AGC
incidence over a 15-year period and examining their age-cohort-
period patterns, we have estimated their respective contributions
to the rising incidence of the oesophagus–cardia adenocarcinoma
in the Netherlands.
MATERIALS AND METHODS
The Netherlands, a country of 16 million inhabitants, has nine
Regional Cancer Registries, hosted by the regional Comprehensive
Cancer Centres, to which both hospital medical record depart-
ments and pathology departments report all malignancies. The
Netherlands Cancer Registry in turn collates these data. The
ascertainment of symptomatic oesophageal cancer in the Nether-
lands is likely to be high, as it practically always results in
endoscopic and histological diagnosis for curative or palliative
interventions (Siersema et al, 2005).
For the 15-year period 1989–2003, the Netherlands Cancer
Registry provided annual age- and gender-specific incidence data
for ACO (the combined data for ICD.O regions C.15.3, C15.4, C15.5
and C15.9) and for AGC (ICD.O region C.16.0), both ICD.O
morphology 8140/3 by 3-year age groups. This allowed estimation
of time trends and age–period–cohort analysis for each cancer by
log-linear Poisson regression models. Incidence rates were also
provided as European standardised rates (ESR) by 5-year age
groups. In addition, ACO incidence data by 5-year age groups were
provided separately for each of the three levels of the oesophagus,
upper-, middle- and lower-third and unspecified (ICD.O regions
C.15.3, C15.4, C15.5 and C15.9).
For the cohort models, a mean year of birth was calculated for
each 3-year age group. The estimated drift parameters constituted
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population size. We used linear splines to test for nonlinear period
and cohort patterns. In any observed annual percentage change,
the choice between a period and a cohort effect could only be made
if one or the other spline was nonlinear. Therefore, instead of one
exponential curve spanning the whole period, we extended the
model to three exponential lines connected by knots at 1993 and
1998 for period estimates, and 1926 and 1944 for those of birth
cohort. In both cases, the knots were placed at (approximately)
one- and two-thirds of the time axis, without attempting to
optimise this choice. Likelihood ratio tests (comparison of scaled
deviances) indicated whether significant nonlinear period or
cohort effects were present (Clayton and Schifflers, 1987a,b). Male
to female ratios were estimated from a model including incidence
year, age group and gender.
RESULTS
Incidence (ESR) and trends by log-linear regression
models
Over the 15-year period 1989–2003, ESR of oesophagus–cardia
adenocarcinoma rose by 34% (from 7.4 10
5 to 10.0 10
5)
in males, by 25% (from 1.7 10
5 to 2.1 10
5) in females and by
33% (from 9.1 10
5 to 12.1 10
5) for both combined.
The ESR and time trends for ACO and AGC by gender for these
years are shown in Figure 1. The mean ESR of the two tumours
over the total 15-year period was practically identical, for ACO,
4.3 10
5 in men and 0.96 10
5 in females and for AGC, 4.3 10
5
in males and 0.92 10
5 in females. Initially, male AGC incidence
was far in excess of that of ACO. However, from 1998 onwards, the
combination of steeply rising ACO incidence and a downward
AGC trend reversed this relationship. A similar, but less
pronounced, pattern was seen in females. The incidence trends,
after correction for age, for both genders over the 15-year period
1989–2003 are shown in Table 1. Annual AGC incidence declined
by  1.7% in males (P¼0.0002) and –1.2% in females (P¼0.05).
In contrast, ACO incidence increased by 7.2% p.a. (Po0.001) for
men but only 3.5% p.a. (P¼0.006) for females. Table 1 also
presents the trends in ACO incidence at three levels of the
oesophagus. In males, these increases were: upper-third, 8.9% p.a.;
middle-third, 6.5% p.a. and lower-third, 8.8% p.a. (Po0.0001
for each, with no significant differences between the three levels).
In females, there were no significant annual increases at the upper-
and middle-third, but, at the lower-third, an annual increase of
6.1% was found, Po0.0001. In 458 of 6538 cases of ACO (7%), no
level was specified, with no discernable trends.
We did observe an unexpected similarity between both genders
in the numbers of cases of ACO at the upper- and the middle-third.
This was the result of a surge in the number of ACO cases in
females over 75 years; upper-third: males 18 (ESR 0.44), females 53
(ESR 0.65); and middle-third: males 146 (ESR 2.6), females 206
(ESR 2.5).
The age- and gender-specific annual increases in ACO incidence
are presented in Table 2. These increases were highest in the 40–
60-year age group, decreasing significantly for both genders at ages
61–84 (P¼0.03). However, in males this decrease amounted to
only 25% against 62% in females. Consequently, the 1.2:1 male/
female ratio at ages 40–60 rose to 2.3:1 at ages 61–84, finally
resulting in annual rates of increase of 7.2% for males and 3.5% for
females.
Age–period–cohort models
The results of the cohort and period estimates are shown in
Table 3. For each tumour, the mean changes in the annual
incidence for each of three periods (before 1926, 1926–1944 and
after 1944) were differentiated by year of birth for cohort effects
and by incidence year for period effects. Significant differences
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Figure 1 The annual European standardised rates for ACO and AGC by
gender for the period 1989–2003.
Table 1 Per annum percentage changes in the incidence rates of adenocarcinoma of the oesophagus, overall and by level, and of the cardia, 1989–2003,
by gender
Oesophageal tumour Gender Numbers observed Incidence ESR Annual %change 95% CI annual change P-values
ACO Males 4949 4.43 +7.2 +6.5; +7.9 o0.001
Overall Females 1589 0.96 +3.5 +2.3; +4.7 o0.001
ACO Males 82 0.07 +8.9 +2.6; +14.0 0.004
Upper-third Females 77 0.04 +1.3  3.8; +6.8 0.6
ACO Males 340 0.3 +6.5 +3.9; +9.3 o0.001
Middle-third Females 302 0.17 +1.0  1.6; +3.7 0.5
ACO Males 4220 3.8 +8.8 +8.1; +9.6 o0.001
Lower-third Females 1059 0.7 +6.1 +4.6; +7.6 o0.001
ACO Males 307 0.28 +1.5  1.1; +4.2 0.3
Unspecified Females 151 0.1  0.4  4.1; +3.3 0.8
AGC Males 4863 4.34  1.7  2.4;  1.1 0.0002
Overall Females 1441 0.92  1.2  2.4;  0.0 0.05
ACO¼adenocarcinoma of the oesophagus; AGC¼adenocarcinoma of the gastric cardia; CI, confidence interval; ESR¼European standardised rates. Source incidence data:
The Netherlands Cancer Registry.
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cohort or period effect.
There were no significant nonlinear cohort or period effects in
males with ACO. In contrast, females with ACO showed a
significant nonlinear cohort effect (P¼0.006), with the greatest
increase in the 1926–44 cohorts, but here again, there was no
significant period effect (P¼0.64).
For AGC, a nonlinear cohort effect was found in males,
Po0.0002, demonstrating a steadily declining trend in cohorts
born after 1926. This was in contrast to the nonlinear cohort effect
in females, P¼0.01, which demonstrated a rising trend in cohorts
born after World War II. Finally, for AGC a nonlinear period effect
in males, P¼0.0001 (Figure 2), partly mirrored in females, P¼0.3,
suggested a decline caused by a period effect setting in around
1995.
DISCUSSION
These results from the Netherlands confirm the worldwide trend
for increasing incidence of oesophagus–cardia adenocarcinoma
(Bollschweiler et al, 2001; El-Serag, 2002). While in the Nether-
lands, this rising trend was very pronounced for ACO, the AGC
incidence rates actually declined for both genders. Our major
finding is that, at least in the Netherlands, the rising incidence of
oesophagus–cardia adenocarcinoma over the past 15 years was
entirely due to ACO, which, despite their clinical similarity, points
to aetiological differences (Wijnhoven et al, 1999).
In the years 1968–1994, ACG incidence was already declining in
the Netherlands (Laheij et al, 1999). However, where previously
(ICD 9) visible Barrett’s oesophagus was considered desirable for
the diagnosis of ACO, current practice is to be guided by
localisation of the major bulk of the tumour (Bytzer et al, 1999;
Driessen et al, 2003). This revision could have resulted in a
diagnostic shift from AGC to ACO, thereby explaining the period
effect observed in the declining AGC incidence. However, in males
this is contradicted on two grounds: (1) by the identical rising
trends in the incidence of ACO localised in the upper- and middle-
third of the oesophagus to that observed in the lower-third
(Table 1). While misclassification in the lower-third might well
have caused a diagnostic shift from AGC to ACO, this would
obviously have been extremely unlikely for the upper- and middle-
third. Since a diagnostic shift limited to females is unlikely, the
absence of these trends in females hardly weighs against this
argument.
(2) A diagnostic shift of a size sufficient to explain the observed
downward period effect in AGC incidence should have been
reflected in a complementary upward period effect in ACO, which,
however, was not observed (Figure 2). We therefore consider both
the rising ACO incidence and the declining AGC incidence to be
genuine.
There was no significant nonlinear male ACO cohort effect,
meaning that the annual changes in ACO incidence did not differ
significantly by year of birth (Table 3). However, the annual
increases were considerable, amounting to over 9% in the youngest
age cohorts. In the absence of factors causing a period effect, such
as a major change in tumour classification or the appearance of a
new carcinogen, and because of the presence of a cohort effect in
females, we are convinced of a cohort effect in males with ACO,
thus confirming the cohort effect for ACO found in US SEER-data
(El-Serag et al, 2002).
The two-fold gender differences in the annual percentage
increases in ACO incidence (Table 1) were surprising, as the
annual incidence increase in Barrett’s oesophagus in the Nether-
lands was recently demonstrated to be equal for both genders (van
Soest et al, 2005). However, the source of this gender difference
was revealed to be a steep dip in the annual increase in ACO
incidence for females, and to a far smaller extent in males, aged
61–84, that is those born between 1905 and 1940 (Table 2). This
dip was not a temporary phenomenon as the increases at ages
40–85þ were calculated separately for each of the 15 years. We
suggest nonsteroidal anti-inflammatory drug (NSAID) use by the
elderly as a possible cause of this dip. Several studies have
suggested a protective effect of NSAIDs against ACO in patients
with Barrett’s oesophagus (Souza et al, 2000; Buttar et al, 2002;
Kaur et al, 2002; Bardou et al, 2004; Gammon et al, 2004; Tsibouris
et al, 2004; Vaughan et al, 2005). In addition, there are marked
gender differences in NSAID use in the elderly (Schnitzer et al,
2001; Helin-Salmivaara et al, 2003). In the Netherlands, the
Integrated Primary Care Information electronic database covering
500000 patients revealed the NSAID user rate, rising from 10%
Table 2 The per annum percentage increase in the incidence rates of
adenocarcinoma of the oesophagus by age and gender
Age bands 40–60 61–66 67–72 73–78 79–84 85+
Males 9.0 5.9 6.0 7.0 7.8 5.5
Females 7.5 4.8 3.6 0.6 2.5 4.3
Table 3 Cohort or period effects for adenocarcinoma of the oesophagus (ACO) and the gastric cardia (AGC) by gender 1989–2003
Cohort effect Period effect
Tumour Gender Drift o1926 1926–44 41944 P-value 1989–93 1994–99 1999–03 P-value
ACO Males +7.2 +7.2 +7.1 +9.1 0.08 +6.8 +6.5 +8.4 0.5
ACO Females +3.5 +2.1 +7.1 +4.0 0.006 +2.9 +2.9 + 5.4 0.6
AGC Males  1.7 +0.1  3.0  3.1 o0.0002 +1.4  1.2  5.9 0.0001
AGC Females  1.2  2.6 +0.1 +4.1 0.01 +1.4  1.4  3.4 0.3
Drift¼per annum percentage change.
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Figure 2 The age–period models for both ACO and AGC in males.
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females (Dr MCJM Sturkenboom, personal communication). In
individuals over the age of 61 with Barrett’s oesophagus, NSAID
use, by postponing or preventing the onset of ACO, is likely to
have contributed to the reduction in the annual rise of ACO
incidence, this effect being more marked in females, consistent
with their higher NSAID consumption.
The declining AGC incidence raises questions about the nature
of AGC and its aetiology. The most commonly used Siewert
classification defines AGC as an adenocarcinoma with its centre
5cm proximal or distal from the anatomical cardia and
distinguishes it into three types. Type I arising from (short
segment) Barrett’s oesophagus and therefore, in our opinion, ACO;
type II, true AGC, arising from the cardiac epithelium or a short
segment of intestinal metaplasia at the oesophagogastric junction;
and type III, subcardial gastric cancer, infiltrating the cardia from
below (Siewert and Stein, 1998). Since it has been suggested that
there are two types, one related to Helicobacter pylori and the other
to gastro-oesophageal reflux (McColl, 2006), AGC may well reflect
the sum of these two opposing aetiologies.
The suspected causes of the increasing ACO incidence in
industrialised countries, increasing obesity and possibly the
declining prevalence of H pylori infection, are both evident in
the Netherlands (Roosendaal et al, 1997; Richter et al, 1998;
Visscher et al, 2002; El-Serag et al, 2005). Mediating their effects
through reflux oesophagitis and Barrett’s oesophagus (Souza and
Spechler, 2005), these factors appear less relevant for AGC, as
demonstrated by a recent meta-analysis of overweight as a risk
factor for gastro-oesophageal reflux disease, which, in marked
contrast to ACO, found only a marginally increased risk of AGC
from obesity (Hampel et al, 2005). Studies of H pylori infection in
AGC also failed to find a significant relationship (Hansen et al,
1999; Wu et al, 2003; Gulmann et al., 2004).
Smoking, however, may well be important in the aetiology of
AGC. In a prospective study with accurate differentiation between
ACO and AGC, AGC was found to be dose-dependently related to
smoking, odds ratio 4.2, whereas the relation with ACO was weak
or absent (Lagergren et al, 2000). A complementary observation
was made in institutionalised intellectually disabled individuals
who do not smoke (van Blankenstein et al, 2004).
The contrasting AGC cohort effects in males and females
(Figure 3) nicely fit the contrasting secular changes in smoking
patterns in Dutch men and women, as implied by a lung cancer
study, which found a steady decline in the number of male
smokers born after 1914. This is in contrast to females, in whom,
since the second half of the 19th century and in successive birth
cohorts, the number of smokers has steadily increased and, after a
relative plateau between 1928-37, has continued to increase, with
numbers doubling in 1945 and later birth cohorts (Barendregt
et al, 2002). The net decline in the AGC incidence is explained by
the 4:1 male/female ratio, with the impact of the declining numbers
of male smokers considerably outweighing that of the rising
number of their female counterparts. We suggest that these
findings lend support to a significant role for smoking in the
aetiology of AGC.
Finally, the conversion of nitrite in saliva by acid into potentially
mutagenic substances such as nitrous acid, nitrosative species
and nitric oxide comprises a less well-established aetiology for
the oesophagus–cardia adenocarcinoma which may have
gained importance by the greater use of nitrogenous fertilizers
after World War II (Spechler, 2002). In patients with Barrett’s
oesophagus, mutagenic nitrite conversion has recently been
shown to occur within the Barrett’s oesophagus segments
(Suzuki et al, 2005). For AGC, this conversion is therefore likely
to be localised in the cardia (McColl, 2005). Whether this
hypothetical factor is still on the increase or has passed its peak
is unknown.
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